Regeneron Pharmaceuticals, Inc.

REGN

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0000872589

D

fourth fifth of 370 graded peers in healthcare

rank 262 of 370; percentile 70.7; sampling error 2.5 points; lower is stronger

A B C D E

D, the sloth



Scoreboard	
Profitability	D/E percentile 78.2
Solvency	B percentile 27.1
Growth and financing	C/D percentile 61.8
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $40.6B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: dilution, distress, fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Feb 4, 2026 262 days before the rescan; latest periodic filing 10-Q received Jul 30, 2026
Last close	$805.34 2026-10-23; market equity $0; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 4, 2026

This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (where applicable, together with its subsidiaries, "Regeneron," "Company," "we," "us," and "our"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 78.2						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing					
Accruals ratio	(1.2%)	(6.6%)	78.2	809	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 27.1					
Twelve-month failure probability	not computable	0.07%			
liabilities and a nearby cover-page share count are required at 2026-06-30					
Altman Z double-prime	9.21	(0.33)	9.8	754	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Current ratio	4.13x	2.94x	44.3	836	2025-12-31
Growth and financing, sleeve percentile 61.8					
Revenue growth, three-year compound	5.6%	10.1%	57.5	413	2025-12-31
Free cash flow growth, three-year compound	(2.7%)	10.9%	77.9	96	2025-12-31
Reinvestment rate	(23.0%)	37.1%	81.6	104	2025-12-31
Asset growth, three years	11.6%	2.1%	30.1	702	2025-12-31
Net share issuance, one year	not computable	2.5%			
raw and split-adjusted prices do not align at 2012-02-10					

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
257	Iovance Biotherapeutics, Inc. (IOVA)	69.4	D	dilution, short runway
258	Lyell Immunopharma, Inc. (LYEL)	69.6	D	dilution, degenerate inputs
259	Rockwell Medical, Inc. (RMTI)	69.9	D	
260	Bioventus Inc. (BVS)	70.2	D	
261	AbCellera Biologics Inc. (ABCL)	70.5	D	
262	Regeneron Pharmaceuticals, Inc. (REGN)	70.7	D	
263	uniQure N.V. (QURE)	71.0	D	fortress balance sheet
264	Bausch & Lomb Corp. (BLCO)	71.3	D	
265	Pennant Group, Inc. (PNTG)	71.5	D	
266	Cumberland Pharmaceuticals Inc. (CPIX)	71.8	D	
267	Bausch Health Companies Inc. (BHC)	72.1	D	

What the price implies

at the 2026-10-23 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	42.8%	7.7%	72
Distance from 52-week high	(5.5%)	(31.4%)	85
EBIT to enterprise value	not computable	(1.5%)	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Free cash flow yield	not computable	(1.0%)	
Book value to price	not computable	0.28	
Sales to price	not computable	0.30	
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	0.14	(0.14)	72

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$2.5B
Operating cash flow, four quarters	$4.7B
Months of runway	not finite
Days since last periodic filing	86 (10-Q received Jul 30, 2026)
Median daily dollar volume, 63 sessions	$505.8M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	$4.5B	2025-12-31	2026-02-04	10-K	26-000008
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$5.0B	2025-12-31	2026-02-04	10-K	26-000008
3	assets	us-gaap:Assets	$40.6B	2025-12-31	2026-02-04	10-K	26-000008
4	assets	us-gaap:Assets	$37.8B	2024-12-31	2026-02-04	10-K	26-000008
5	current assets	us-gaap:AssetsCurrent	$18.0B	2025-12-31	2026-02-04	10-K	26-000008
6	current liabilities	us-gaap:LiabilitiesCurrent	$4.4B	2025-12-31	2026-02-04	10-K	26-000008
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$35.8B	2025-12-31	2026-02-04	10-K	26-000008
8	operating income	us-gaap:OperatingIncomeLoss	$3.6B	2025-12-31	2026-02-04	10-K	26-000008
9	book equity	us-gaap:StockholdersEquity	$31.3B	2025-12-31	2026-02-04	10-K	26-000008
10	liabilities	us-gaap:Liabilities	$9.3B	2025-12-31	2026-02-04	10-K	26-000008
11	operating income	us-gaap:OperatingIncomeLoss	$4.0B	2023-12-31	2026-02-04	10-K	26-000008
12	interest expense	us-gaap:InterestExpense	$73.0M	2023-12-31	2024-02-05	10-K	24-000009
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$14.3B	2025-12-31	2026-02-04	10-K	26-000008
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$14.2B	2024-12-31	2026-02-04	10-K	26-000008
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$13.1B	2023-12-31	2026-02-04	10-K	26-000008
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$12.2B	2022-12-31	2025-02-05	10-K	25-000011
17	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$898.4M	2025-12-31	2026-02-04	10-K	26-000008
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$4.4B	2024-12-31	2026-02-04	10-K	26-000008
19	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$755.9M	2024-12-31	2026-02-04	10-K	26-000008
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$4.6B	2023-12-31	2026-02-04	10-K	26-000008
21	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$718.6M	2023-12-31	2026-02-04	10-K	26-000008
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$5.0B	2022-12-31	2025-02-05	10-K	25-000011
23	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$590.1M	2022-12-31	2025-02-05	10-K	25-000011
24	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$543.7M	2025-12-31	2026-02-04	10-K	26-000008
25	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$5.2B	2025-12-31	2026-02-04	10-K	26-000008

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

26	income tax	us-gaap:IncomeTaxExpenseBenefit	$725.8M	2025-12-31	2026-02-04	10-K	26-000008
27	current assets	us-gaap:AssetsCurrent	$18.7B	2024-12-31	2026-02-04	10-K	26-000008
28	current liabilities	us-gaap:LiabilitiesCurrent	$3.9B	2024-12-31	2026-02-04	10-K	26-000008
29	assets	us-gaap:Assets	$33.1B	2023-12-31	2025-02-05	10-K	25-000011
30	assets	us-gaap:Assets	$29.2B	2022-12-31	2024-02-05	10-K	24-000009
31	shares outstanding	dei:EntityCommonStockSharesOutstanding	91,779,465	2012-02-10	2012-02-21	10-K	12-000709
32	shares outstanding	dei:EntityCommonStockSharesOutstanding	87,777,008	2011-02-11	2011-02-17	10-K	11-000263

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.